유선암 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Breast Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,828,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,311,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,279,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

유선암 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 유선암 치료 시장 규모는 2030년까지 428억 7,000만 달러에 달할 것으로 예측되며, 2024-2030년 CAGR은 9.1%로 성장할 것으로 예측됩니다.

이러한 성장은 치료 기술의 발전, 유방암의 유병률 증가, 맞춤형 의료에 대한 관심 증가가 큰 원동력이 되고 있습니다. 미국 유방암 재단에 따르면 미국 여성 8명 중 1명이 일생 동안 유방암 진단을 받을 것이며, 2024년에는 약 310,720명의 여성과 2,800명의 남성이 침윤성 유방암 진단을 받을 것으로 예상하고 있습니다. 가장 초기에 국소화된 유방암의 5년 상대생존율은 99%에 달할 전망입니다. 조기 발견과 치료의 발전으로 최근 수년간 생존율이 크게 향상되어 현재 미국에는 400만 명 이상의 유방암 생존자가 있습니다.

유방암의 흔한 형태인 유방암은 표적치료, 면역치료, 호르몬 치료 등 다양한 혁신적 치료법을 통해 치료되고 있습니다. 시장 규모의 확대는 치료 효과를 높이고 환자의 예후를 개선하는 새로운 약물과 치료법이 지속적으로 개발되고 있기 때문입니다. 또한 유방암에 대한 인식이 높아지고 조기 발견의 중요성이 부각되면서 첨단 치료 옵션에 대한 수요가 증가하고 있습니다.

고령화 및 유병률 증가와 함께 전 세계에서 유방암의 부담이 증가하고 있는 것도 시장 확대에 박차를 가하고 있습니다. 첨단 치료법을 찾는 환자들이 늘어나고 의료 시스템이 첨단 기술에 투자함에 따라 유선암 치료 시장은 크게 성장할 것으로 예상됩니다. 유전체 프로파일링, 바이오마커 식별 등 정밀의료 분야의 기술 발전은 보다 개인화된 치료 접근법을 가능하게 하고 있습니다. 이러한 기술 혁신은 부작용을 최소화하면서 암세포를 보다 효과적으로 표적화하여 환자의 전반적인 경험을 향상시킬 수 있습니다. 또한 현재 진행 중인 연구 및 임상시험은 새로운 치료법 및 병용 요법을 도입할 가능성이 높으며, 이는 시장 성장을 더욱 촉진할 수 있습니다.

유선암 치료 시장 보고서 - 하이라이트

• 표적치료제 부문은 2023년 27.6%로 가장 큰 점유율을 차지할 것으로 예상됩니다. 이는 보다 정밀하고 효과적인 치료법으로의 전환을 반영하는 것으로, 유방암 치료에 있으며, 표적치료제의 혁신적인 영향력을 강조하고 있습니다.
• 병원 부문은 2023년 60.0% 이상의 가장 큰 점유율을 차지할 것으로 예상됩니다. 이러한 성장은 유방암의 높은 유병률로 인해 병원 기반 치료에 대한 수요가 크게 증가했기 때문으로 분석됩니다.
• 시장의 유명 기업은 Merck & Co; Bristol Myers Squibb; Kyowa Kirin; Eisai Co. Ltd; Sanofi; Pfizer Inc; AstraZeneca; Novartis AG; Eli Lilly and Company; F. Hoffmann La Roche AG 등입니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 유선암 치료 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 유선암 치료 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
  • COVID-19의 영향

제4장 세계의 유선암 치료 시장 : 치료별 추정·동향 분석

• 세계의 유선암 치료 시장 : 치료 대시보드
• 세계의 유선암 치료 시장 : 치료 변동 분석
• 세계의 유선암 치료 시장, 치료별
• 화학요법
• 표적치료
• 호르몬 요법
• 면역치료
• 방사선 치료
• 기타

제5장 유선암 치료 시장 : 최종 용도별 추정·동향 분석

• 세계의 유선암 치료 시장 : 최종 용도 대시보드
• 세계의 유선암 치료 시장 : 최종 용도 변동 분석
• 세계의 유선암 치료 시장, 최종 용도별
• 병원
• 전문 클리닉
• 기타

제6장 유선암 치료 시장 : 지역별 추정·동향 분석, 치료별, 최종 용도별.

• 지역 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년 :
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제7장 경쟁 구도

• 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 히트맵 분석, 2023년
• 기업 개요
  • Merck &Co
  • Bristol Myers Squiib
  • Kyowa Kirin
  • Eisai Co.Ltd
  • Sanofi
  • Pfizer Inc
  • AstraZeneca
  • Novartis AG
  • Eli Lilly and Company
  • F. Hoffmann La Roche AG

KSA

영문 목차

영문목차

Breast Adenocarcinoma Treatment Market Growth & Trends:

The global breast adenocarcinoma treatment market size is expected to reach USD 42.87 billion by 2030 and is projected to grow at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is significantly driven by the advancements in treatment technologies, the increasing prevalence of breast adenocarcinoma, and a growing focus on personalized medicine. According to the National Breast Cancer Foundation, in the U.S., 1 in 8 women will be diagnosed with breast cancer during their lifetime. For 2024, an estimated 310,720 women and 2,800 men are expected to be diagnosed with invasive breast cancer. The 5-year relative survival rate for breast cancer diagnosed at its earliest, localized stage is 99%. Advances in early detection and treatment have markedly improved survival rates in recent years, resulting in over 4 million breast cancer survivors currently living in the U.S.

Breast adenocarcinoma, a common form of breast cancer, is being addressed through a range of innovative treatments that include targeted therapies, immunotherapies, and hormonal therapies. The rise in market size can be attributed to the continual development of new drugs and therapies that enhance treatment efficacy and improve patient outcomes. In addition, the increasing awareness of breast cancer and the importance of early detection are contributing to a higher demand for advanced treatment options.

The increasing global burden of breast cancer, coupled with an aging population and rising incidence rates, is also fueling market expansion. As more patients seek advanced treatment options and healthcare systems invest in cutting-edge technologies, the market for breast adenocarcinoma treatments is set to grow significantly. Technological advancements in precision medicine, such as genomic profiling and biomarker identification, are enabling more personalized treatment approaches. These innovations allow for more effective targeting of cancer cells while minimizing side effects, thus enhancing the overall patient experience. Furthermore, ongoing research and clinical trials are likely to introduce novel therapies and combination treatments that could further drive market growth.

Breast Adenocarcinoma Treatment Market Report Highlights:

• The targeted therapy segment held the largest share of 27.6 % in 2023. This prominence underscores the transformative impact of targeted therapies on breast cancer treatment, reflecting a shift towards more precise and effective treatment modalities.
• The hospitals segment held the largest share of more than 60.0% in 2023. This growth is largely due to the high prevalence of breast cancer, which drives significant demand for hospital-based treatments.
• Some of the prominent players in market are Merck & Co; Bristol Myers Squibb; Kyowa Kirin; Eisai Co. Ltd; Sanofi; Pfizer Inc; AstraZeneca; Novartis AG; Eli Lilly and Company; F. Hoffmann La Roche AG

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Treatment
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Breast Adenocarcinoma Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Breast Cancer
    • 3.2.1.2. Advancements In Treatment Modalities
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent Regulation And Approvals
    • 3.2.2.2. High Cost of Treatments
• 3.3. Breast Adenocarcinoma Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. COVID-19 Impact

Chapter 4. Global Breast Adenocarcinoma Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Breast Adenocarcinoma Treatment Market: Treatment Dashboard
• 4.2. Global Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
• 4.3. Global Breast Adenocarcinoma Treatment Market, Treatment
• 4.4. Chemotherapy
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.5. Targeted Therapy
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.6. Hormonal Therapy
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.7. Immunotherapy
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.8. Radiation Therapy
  • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.9. Other
  • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Breast Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Breast Adenocarcinoma Treatment Market: End Use Dashboard
• 5.2. Global Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
• 5.3. Global Breast Adenocarcinoma Treatment Market, End Use
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.5. Specialty Clinics
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.6. Others
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Breast Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use.

• 6.1. Regional Market Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.6. Singapore
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments and Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company heat map analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. Merck & Co
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Bristol Myers Squiib
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Kyowa Kirin
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Eisai Co.Ltd
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Sanofi
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Pfizer Inc
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. AstraZeneca
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Novartis AG
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Eli Lilly and Company
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. F. Hoffmann La Roche AG
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives

관련자료